These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 35409188)
1. Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. Allegretta C; D'Amico E; Manuti V; Avolio C; Conese M Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409188 [TBL] [Abstract][Full Text] [Related]
2. Emerging concepts in the treatment of optic neuritis: mesenchymal stem cell-derived extracellular vesicles. Aneesh A; Liu A; Moss HE; Feinstein D; Ravindran S; Mathew B; Roth S Stem Cell Res Ther; 2021 Dec; 12(1):594. PubMed ID: 34863294 [TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Central Nervous System Demyelinating Disorders. Touma L; Muccilli A Neurol Clin; 2022 Feb; 40(1):113-131. PubMed ID: 34798965 [TBL] [Abstract][Full Text] [Related]
4. Atypical Pediatric Demyelinating Diseases of the Central Nervous System. Troxell RM; Christy A Curr Neurol Neurosci Rep; 2019 Nov; 19(12):95. PubMed ID: 31773416 [TBL] [Abstract][Full Text] [Related]
5. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Di Pauli F; Berger T Front Immunol; 2018; 9():2753. PubMed ID: 30555462 [TBL] [Abstract][Full Text] [Related]
6. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Hino-Fukuyo N; Haginoya K; Nakashima I; Sato DK; Takahashi T; Misu T; Fujihara K; Hirose M; Kakisaka Y; Uematsu M; Kobayashi T; Kure S Brain Dev; 2015 Oct; 37(9):849-52. PubMed ID: 25748628 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles as novel cell-free therapy for treatment of autoimmune disorders. Kahmini FR; Shahgaldi S Exp Mol Pathol; 2021 Feb; 118():104566. PubMed ID: 33160961 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases. Műzes G; Sipos F Cells; 2022 Jul; 11(15):. PubMed ID: 35892597 [TBL] [Abstract][Full Text] [Related]
9. Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases. Huldani H; Abdalkareem Jasim S; Olegovich Bokov D; Abdelbasset WK; Nader Shalaby M; Thangavelu L; Margiana R; Qasim MT Int Immunopharmacol; 2022 May; 106():108634. PubMed ID: 35193053 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic prospects of MicroRNAs carried by mesenchymal stem cells-derived extracellular vesicles in autoimmune diseases. Liu H; Chen Y; Yin G; Xie Q Life Sci; 2021 Jul; 277():119458. PubMed ID: 33831424 [TBL] [Abstract][Full Text] [Related]
11. Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases. Spadaro M; Meinl E Methods Mol Biol; 2016; 1304():99-104. PubMed ID: 25814289 [TBL] [Abstract][Full Text] [Related]
12. Pediatric inflammatory demyelinating disorders and mimickers: How to differentiate with MRI? Pereira FV; Jarry VM; Castro JTS; Appenzeller S; Reis F Autoimmun Rev; 2021 May; 20(5):102801. PubMed ID: 33727154 [TBL] [Abstract][Full Text] [Related]
13. [Molecular pathology of multiple sclerosis and neuromyelitis optica]. Masaki K Nihon Rinsho; 2014 Nov; 72(11):1909-17. PubMed ID: 25518370 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers in Rare Demyelinating Disease of the Central Nervous System. Boziki M; Sintila SA; Ioannidis P; Grigoriadis N Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182495 [TBL] [Abstract][Full Text] [Related]
15. Dental Mesenchymal Stem Cell Secretome: An Intriguing Approach for Neuroprotection and Neuroregeneration. Gugliandolo A; Mazzon E Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008878 [TBL] [Abstract][Full Text] [Related]
16. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. Peschl P; Schanda K; Zeka B; Given K; Böhm D; Ruprecht K; Saiz A; Lutterotti A; Rostásy K; Höftberger R; Berger T; Macklin W; Lassmann H; Bradl M; Bennett JL; Reindl M J Neuroinflammation; 2017 Oct; 14(1):208. PubMed ID: 29070051 [TBL] [Abstract][Full Text] [Related]
17. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M; Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis. Jafarinia M; Alsahebfosoul F; Salehi H; Eskandari N; Azimzadeh M; Mahmoodi M; Asgary S; Ganjalikhani Hakemi M J Cell Physiol; 2020 Nov; 235(11):8779-8790. PubMed ID: 32329062 [TBL] [Abstract][Full Text] [Related]
19. Inflammatory demyelinating diseases of the central nervous system. Höftberger R; Lassmann H Handb Clin Neurol; 2017; 145():263-283. PubMed ID: 28987175 [TBL] [Abstract][Full Text] [Related]
20. Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. Riazifar M; Mohammadi MR; Pone EJ; Yeri A; Lässer C; Segaliny AI; McIntyre LL; Shelke GV; Hutchins E; Hamamoto A; Calle EN; Crescitelli R; Liao W; Pham V; Yin Y; Jayaraman J; Lakey JRT; Walsh CM; Van Keuren-Jensen K; Lotvall J; Zhao W ACS Nano; 2019 Jun; 13(6):6670-6688. PubMed ID: 31117376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]